Clinical trials in Foggia – page 6

125 clinical trials in Foggia, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Foggia at a glance

125

clinical trials

Research sites2

Quick filters

125 trials in Foggia

Open in trial search

Metabolic dysfunction-associated steatohepatitis

Not yet recruiting

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational

Italy

Participants:18–64 years · 65+ years
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis

Not yet recruiting

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational

Italy

Participants:18–64 years · 65+ years
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Gemcitabine
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Transitional cell carcinoma

Not yet recruiting

ctDNA‑guided Study of Enfortumab Vedotin plus Pembrolizumab in Untreated Patients with Advanced Urothelial Carcinoma

Registered drugNo placebo

ctDNA‑guided Study of Enfortumab Vedotin plus Pembrolizumab in Untreated Patients with Advanced Urothelial Carcinoma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Enfortumab Vedotin
Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Contact Research Centre

Hormone-refractory prostate cancer

Not yet recruiting

Phase III Randomized Open‑Label Trial of BNT324 vs Docetaxel Plus Prednisone in Patients with Metastatic Castration‑Resistant Prostate Cancer

Registered drugNo placebo

Phase III Randomized Open‑Label Trial of BNT324 vs Docetaxel Plus Prednisone in Patients with Metastatic Castration‑Resistant Prostate Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:BioNTech SE

Contact Research Centre

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Admilparant
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Transitional cell carcinoma metastatic

Not yet recruiting

Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma After Second-Line Platinum-Based Chemotherapy

Registered drugNo placebo

Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma After Second-Line Platinum-Based Chemotherapy

Registered drugNo placebo

Italy

Participants:18–64 years
Substances:Avelumab
Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Contact Research Centre

Idiopathic pulmonary fibrosis

Not yet recruiting

A study to evaluate the safety and effectiveness of zampilimab in people with idiopathic pulmonary fibrosis

Investigational

A study to evaluate the safety and effectiveness of zampilimab in people with idiopathic pulmonary fibrosis

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Zampilimab
Sponsor:Chiesi Farmaceutici S.p.A.

Contact Research Centre

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Admilparant
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Idiopathic pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Investigational

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Admilparant
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Pancreatic carcinoma metastatic+1

Not yet recruiting

A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss

Registered drug

A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Ponsegromab
Sponsor:Pfizer Inc.

Contact Research Centre

Conjunctivitis allergic

Not yet recruiting

Testing Intralymphatic Allergen Immunotherapy for Teenagers and Adults with Grass Pollen Allergy Causing Hay Fever or Asthma

Registered drug

Testing Intralymphatic Allergen Immunotherapy for Teenagers and Adults with Grass Pollen Allergy Causing Hay Fever or Asthma

Registered drug

Italy

Participants:18–64 years · 65+ years
Sponsor:University Of Foggia

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Foggia

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic cancers and advanced treatment approaches. Studies include investigations of novel therapies for prostate cancer, colorectal cancer, and various forms of leukemia.

Castration-resistant Prostate Cancer
Acute Myeloid Leukemia
HER2+ Colorectal Cancer

Research emphasizes targeted therapies and combination treatments to improve patient outcomes.

02 Neurological Disorders

Comprehensive studies exploring treatments for multiple sclerosis and neurodegenerative conditions. Research includes evaluation of new therapeutic agents and disease-modifying treatments.

Multiple Sclerosis Management
Alzheimer's Disease
Radiologically Isolated Syndrome

Focus on improving cognitive function and disease progression management.

03 Cardiovascular Health

Advanced research into heart failure prevention and cardiovascular disease management. Studies evaluate new therapeutic combinations and preventive strategies.

Heart Failure Prevention
Atrial Fibrillation
Type 2 Diabetes Cardiovascular Outcomes

Emphasis on reducing cardiovascular events and improving patient outcomes.

Back to Italy All countries